Stock listing
BOATS:CRVO CervoMed Inc. Stock
US listing (BOATS) of CervoMed Inc. · home listing NASDAQ:CRVO
Follow CervoMed Inc. into a list and get an email when it puts out news.
Home listing price · NASDAQ:CRVO
$1.60 USD -0.15 (-8.6%)
Close on Oct 30, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:CRVO
- Day range
- $1.60 – $1.77 USDOct 30, 2026
- Volume
- 585,339 sharesOct 30, 2026
- Market cap
- $24.19M USDAt the close on Oct 30, 2026 · price × 15.12M shares outstanding
- 52-week range
- $1.60 – $10.00 USDLowest and highest trades, Oct 31, 2025 – Oct 30, 2026
- Traded on an average day
- $754,619 USDMedian day 213,579 shares · last 3 months, Jul 30, 2026 – Oct 30, 2026
Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:CRVO · Home | $1.60 USD | -0.15 (-8.6%) | 585,339 | $1.71 | $1.77 | $1.60 | $1.75 | Close on Oct 30, 2026 |
| Frankfurt:DP8 | €1.53 EUR | -0.45 (-22.7%) | — | €1.53 | €1.53 | €1.53 | €1.98 | Close on Oct 30, 2026 |
Daily closes
Last 3 months, Jul 30, 2026 – Oct 30, 2026 · NASDAQ:CRVO · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $1.60 | -0.15 | -8.6% | $1.71 | $1.77 | $1.60 | 585,339 | |
| $1.75 | -0.46 | -20.8% | $2.17 | $2.18 | $1.66 | 1,168,877 | |
| $2.21 | -0.01 | -0.5% | $2.21 | $2.27 | $2.14 | 201,600 | |
| $2.22 | -0.02 | -0.9% | $2.215 | $2.30 | $2.18 | 150,558 | |
| $2.24 | -0.07 | -3.0% | $2.29 | $2.29 | $2.18 | 103,966 | |
| $2.31 | +0.07 | +3.1% | $2.23 | $2.33 | $2.22 | 111,783 | |
| $2.24 | -0.10 | -4.3% | $2.29 | $2.35 | $2.23 | 97,663 | |
| $2.34 | +0.05 | +2.2% | $2.31 | $2.41 | $2.31 | 79,257 | |
| $2.29 | -0.02 | -0.9% | $2.28 | $2.406 | $2.28 | 136,346 | |
| $2.31 | +0.07 | +3.1% | $2.24 | $2.35 | $2.18 | 206,704 | |
| $2.24 | -0.01 | -0.4% | $2.23 | $2.30 | $2.22 | 98,726 | |
| $2.25 | -0.04 | -1.7% | $2.26 | $2.31 | $2.213 | 201,191 | |
| $2.29 | +0.02 | +0.9% | $2.22 | $2.41 | $2.13 | 497,193 | |
| $2.27 | -0.24 | -9.6% | $2.50 | $2.53 | $2.17 | 542,057 | |
| $2.51 | -0.71 | -22.0% | $2.75 | $2.79 | $2.42 | 892,095 | |
| $3.22 | -0.06 | -1.8% | $3.26 | $3.335 | $3.166 | 237,328 | |
| $3.28 | +0.10 | +3.1% | $3.15 | $3.31 | $3.13 | 341,949 | |
| $3.18 | -0.16 | -4.8% | $3.26 | $3.36 | $3.13 | 309,461 | |
| $3.34 | +0.03 | +0.9% | $3.36 | $3.44 | $3.11 | 470,492 | |
| $3.31 | +0.29 | +9.6% | $3.13 | $3.35 | $3.06 | 648,749 | |
| $3.02 | +0.09 | +3.1% | $2.96 | $3.07 | $2.881 | 241,802 | |
| $2.93 | -0.04 | -1.3% | $2.98 | $2.98 | $2.86 | 175,071 | |
| $2.97 | +0.09 | +3.1% | $2.91 | $3.05 | $2.75 | 375,542 | |
| $2.88 | +0.21 | +7.9% | $2.70 | $2.92 | $2.67 | 455,792 | |
| $2.67 | +0.13 | +5.1% | $2.55 | $2.68 | $2.54 | 171,059 | |
| $2.54 | +0.02 | +0.8% | $2.52 | $2.63 | $2.52 | 106,090 | |
| $2.52 | +0.01 | +0.4% | $2.46 | $2.53 | $2.43 | 91,009 | |
| $2.51 | -0.02 | -0.8% | $2.59 | $2.60 | $2.50 | 123,577 | |
| $2.53 | +0.12 | +5.0% | $2.43 | $2.61 | $2.42 | 260,726 | |
| $2.41 | -0.02 | -0.8% | $2.47 | $2.49 | $2.41 | 109,104 | |
| $2.43 | -0.12 | -4.7% | $2.53 | $2.575 | $2.43 | 180,861 | |
| $2.55 | +0.11 | +4.5% | $2.53 | $2.601 | $2.48 | 119,434 | |
| $2.44 | -0.01 | -0.4% | $2.45 | $2.519 | $2.40 | 100,328 | |
| $2.45 | -0.08 | -3.2% | $2.53 | $2.53 | $2.43 | 106,984 | |
| $2.53 | -0.04 | -1.6% | $2.54 | $2.58 | $2.49 | 128,295 | |
| $2.57 | +0.09 | +3.6% | $2.54 | $2.64 | $2.50 | 234,572 | |
| $2.48 | -0.03 | -1.2% | $2.50 | $2.53 | $2.47 | 114,864 | |
| $2.51 | -0.02 | -0.8% | $2.53 | $2.54 | $2.47 | 156,009 | |
| $2.53 | -0.03 | -1.2% | $2.58 | $2.58 | $2.42 | 393,938 | |
| $2.56 | +0.02 | +0.8% | $2.54 | $2.58 | $2.52 | 108,604 | |
| $2.54 | -0.10 | -3.8% | $2.66 | $2.665 | $2.52 | 199,035 | |
| $2.64 | +0.07 | +2.7% | $2.55 | $2.65 | $2.55 | 134,532 | |
| $2.57 | -0.06 | -2.3% | $2.58 | $2.67 | $2.55 | 183,584 | |
| $2.63 | +0.03 | +1.2% | $2.56 | $2.64 | $2.55 | 94,998 | |
| $2.60 | -0.04 | -1.5% | $2.64 | $2.67 | $2.55 | 264,545 | |
| $2.64 | -0.01 | -0.4% | $2.65 | $2.67 | $2.61 | 112,169 | |
| $2.65 | 0.00 | 0.0% | $2.61 | $2.67 | $2.601 | 93,644 | |
| $2.65 | +0.02 | +0.8% | $2.69 | $2.73 | $2.60 | 220,453 | |
| $2.63 | +0.01 | +0.4% | $2.65 | $2.65 | $2.57 | 288,040 | |
| $2.62 | +0.06 | +2.3% | $2.60 | $2.64 | $2.56 | 269,568 | |
| $2.56 | -0.15 | -5.5% | $2.70 | $2.71 | $2.50 | 417,323 | |
| $2.71 | +0.10 | +3.8% | $2.67 | $2.87 | $2.62 | 531,660 | |
| $2.61 | 0.00 | 0.0% | $2.59 | $2.65 | $2.55 | 318,961 | |
| $2.61 | -0.12 | -4.4% | $2.82 | $2.82 | $2.55 | 448,464 | |
| $2.73 | -0.20 | -6.8% | $2.99 | $2.99 | $2.68 | 608,534 | |
| $2.93 | -0.14 | -4.6% | $3.11 | $3.19 | $2.91 | 286,210 | |
| $3.07 | -0.02 | -0.6% | $3.07 | $3.14 | $3.01 | 237,781 | |
| $3.09 | +0.23 | +8.0% | $2.95 | $3.20 | $2.932 | 791,272 | |
| $2.86 | -0.01 | -0.3% | $2.87 | $2.875 | $2.66 | 384,198 | |
| $2.87 | +0.11 | +4.0% | $2.84 | $2.88 | $2.78 | 194,393 | |
| $2.76 | -0.05 | -1.8% | $2.81 | $2.96 | $2.595 | 624,513 | |
| $2.81 | +0.01 | +0.4% | $2.81 | $2.865 | $2.73 | 269,281 | |
| $2.80 | +0.20 | +7.7% | $2.69 | $2.85 | $2.66 | 680,690 | |
| $2.60 | +0.02 | +0.8% | $2.60 | $2.67 | $2.585 | 122,549 | |
| $2.58 | +0.06 | +2.4% | $2.51 | $2.60 | $2.46 | 238,564 | |
| $2.52 | +0.04 | +1.6% | $2.46 | $2.56 | $2.43 | 187,117 |
- Ticker
- BOATS:CRVO
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- BOATS
- Currency
- USD
What changed lately
Latest news release · Oct 29, 2026
CervoMed Announces Publication of Two Peer-Reviewed Research Articles Supporting Neflamapimod as a Potential Treatment for Dementia with Lewy Bodies (DLB)
Latest deck · March 2026
AD/PD 2026
Conference · 18 slides
Latest news
CervoMed Announces Publication of Two Peer-Reviewed Research Articles Supporting Neflamapimod as a Potential Treatment for Dementia with Lewy Bodies (DLB)
Oct 29, 2026
Closed $1.75 (-20.8%) on Oct 29, 2026
CervoMed Presents Initial Results of Phase 2a Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Showing Positive Effects on a Key Neurodegeneration Biomarker in Late-Breaking Oral Session at ISFTD 2026
Oct 12, 2026
Closed $2.51 (-22.0%) on Oct 12, 2026
CervoMed Announces Pharmacokinetic Results with New Neflamapimod Oral Tablet Formulation and Secures FDA Removal of Drug Exposure Limit
Sep 28, 2026
Closed $2.67 (+5.1%) on Sep 28, 2026
CervoMed to Participate in the 5th Annual ROTH Healthcare Opportunities Conference
Sep 22, 2026
Closed $2.53 (+5.0%) on Sep 22, 2026
CervoMed Announces Initial Results from the Phase 2a Clinical Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Have Been Accepted as a Late-Breaking Oral Session at ISFTD 2026
Sep 10, 2026
Closed $2.48 (-1.2%) on Sep 10, 2026
CervoMed to Participate in September Investor Conferences
Sep 8, 2026
Closed $2.53 (-1.2%) on Sep 8, 2026
CervoMed Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
Aug 10, 2026
Closed $2.86 (-0.3%) on Aug 10, 2026
CervoMed to Participate in Fireside Chat to Highlight Recent Progress in the Neflamapimod Clinical Development Program at the Canaccord Genuity 46th Annual Growth Conference
Aug 5, 2026
Closed $2.81 (+0.4%) on Aug 5, 2026
Decks
AD/PD 2026
Conference · 18 slides · March 2026
CTAD 2025
Conference · 25 slides · Dec 4, 2025
Conference Presentation (June 2025)
Conference · 20 slides · June 2025
Technical Presentation (January 2025)
Technical · 22 slides · Jan 31, 2025
CervoMed Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 31 in the last 12 months · 77 in all · newest Oct 29, 2026 · oldest 2023
- Decks
- 16 decks · latest March 2026
Where CervoMed Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:CRVO · Home listing | NASDAQ | United States | USD |
| LS Exchange:A3ES01 | LS Exchange | Germany | EUR |
| Lang & Schwarz:A3ES01 | Lang & Schwarz | Germany | EUR |
| BOATS:CRVO · This page | BOATS | United States | USD |
| Tradegate:DP8 | Tradegate | Germany | EUR |
| Frankfurt:DP8 | Frankfurt | Germany | EUR |
| Stuttgart:DP8 | Stuttgart | Germany | EUR |
Log in to ask 6ix AI your own questions about CervoMed Inc.